Peptide Inhibitors for SARS-CoV-2 Methyltransferase
Summary
The USPTO granted Patent US12605423B2 to United Arab Emirates University for synthetic peptide inhibitors designed to inhibit SARS-CoV-2 replication through targeting of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14) for COVID-19 treatment. The patent covers Peptide P3, a synthetic analog of amino acids 89-96 of the SARS-CoV-2 non-structural protein 10 (NSP10), modified to enhance cell membrane penetration.
What changed
The USPTO issued Patent US12605423B2 to United Arab Emirates University, granting exclusive rights to synthetic peptide compositions designed to inhibit SARS-CoV-2 replication through Methyltransferase complex inhibition (NSP10/NSP16 and NSP10/NSP14). The patent covers Peptide P3, derived from amino acids 89-96 of the SARS-CoV-2 NSP10 protein with a Cysteine-to-Methionine modification, formulated to penetrate cell membranes for treating moderate to severe COVID-19.
For biotech and pharmaceutical companies developing antiviral therapeutics, this patent establishes prior art in the peptide inhibitor space targeting SARS-CoV-2 methyltransferases. Companies pursuing similar peptide-based approaches for COVID-19 or related coronaviruses should conduct freedom-to-operate analyses and consider licensing discussions with the assignee.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Peptide inhibitors targeting methyltransfer mechanism of SARS-CoV-2
Grant US12605423B2 Kind: B2 Apr 21, 2026
Assignee
United Arab Emirates University
Inventors
Abdulla Mahboob
Abstract
Synthetic peptides mimicking the nsp10 sequence in the region interacting with nsp16 capable of penetrating cell membranes and inhibiting SARS-CoV-2 replication for the treatment of moderate to severe COVID-19. The invention relates to peptides inhibiting SARS-CoV-2 replication, likely through inhibition of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14). The peptide of the present invention, P3, contains sequences corresponding to amino acids 89-96 of the non-structural protein 10 (NSP10) of SARS-CoV-2, with the only Cysteine modified to a Methionine. This peptide was made based on two previous designs P1 and P2, which constituted the amino acids 68-96 of the NSP10 protein of SARS-CoV-2.
CPC Classifications
C07K 14/005 C07K 2319/00 C07K 2319/70 C07K 14/165 C07K 16/10 A61K 2039/525 A61K 47/6911 A61P 31/14 A61P 31/12 G01N 2333/165
Filing Date
2021-09-08
Application No.
17469491
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.